MCID: INT079
MIFTS: 60

Intrahepatic Cholangiocarcinoma

Categories: Rare diseases, Cancer diseases, Liver diseases, Gastrointestinal diseases

Aliases & Classifications for Intrahepatic Cholangiocarcinoma

MalaCards integrated aliases for Intrahepatic Cholangiocarcinoma:

Name: Intrahepatic Cholangiocarcinoma 12 49 14 69
Cholangiocarcinoma 41 69
Peripheral Intrahepatic Cholangiocarcinoma 69
Intrahepatic Bile Duct Carcinoma 12
Peripheral Cholangiocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4928
ICD10 32 C22.1
MeSH 41 D018281
NCIt 46 C35417
SNOMED-CT 64 109842005

Summaries for Intrahepatic Cholangiocarcinoma

NIH Rare Diseases : 49 Intrahepatic cholangiocarcinoma is a cancer that develops in the cells within the bile ducts; both inside and outside the liver. The terms cholangiocarinoma and bile duct cancer are often used to refer to the same condition. This condition occurs slightly more often in males than females and usually affects people who are between 50-70 years old. Signs and symptoms of intrahepatic cholangiocarcinoma include jaundice, abdominal pain, fever, weight loss, weakness and itching. Treatment options may include surgery to remove the bile duct and parts of the liver, chemotherapy and radiation. Last updated: 4/1/2014

MalaCards based summary : Intrahepatic Cholangiocarcinoma, also known as cholangiocarcinoma, is related to mucinous intrahepatic cholangiocarcinoma and cholangiocarcinoma, and has symptoms including malaise and abdominal pain. An important gene associated with Intrahepatic Cholangiocarcinoma is MUC4 (Mucin 4, Cell Surface Associated), and among its related pathways/superpathways are Innate Immune System and HIV Life Cycle. The drugs Cisplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and endothelial, and related phenotypes are Decreased cell migration and Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance

Related Diseases for Intrahepatic Cholangiocarcinoma

Diseases related to Intrahepatic Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 303)
# Related Disease Score Top Affiliating Genes
1 mucinous intrahepatic cholangiocarcinoma 34.5 MUC2 MUC5AC
2 cholangiocarcinoma 32.1 AFP CDH1 KRAS KRT19 KRT20 KRT7
3 lymphoepithelioma-like carcinoma 30.5 CDH1 KRT20 KRT7 MUC1
4 horseshoe kidney 30.5 EGFR KRT20 KRT7
5 cystadenocarcinoma 30.4 KRT7 MUC1 MUC2 TP53
6 adenoma 30.3 CTNNB1 KRAS KRT7 MUC2 MUC5AC TP53
7 glioblastoma 30.2 EGFR IDH1 IDH2 TP53
8 lung squamous cell carcinoma 30.0 CDH1 EGFR FGFR2 KRAS KRT19 TP53
9 gallbladder cancer 29.8 AFP CDH1 EGFR KRAS MUC1 MUC2
10 biliary papillomatosis 29.6 KRAS KRT19 KRT20 KRT7 MUC1 MUC2
11 adenocarcinoma 29.5 CDH1 CTNNB1 EGFR EPCAM FGFR2 KRAS
12 pancreas adenocarcinoma 29.5 CDH1 CTNNB1 EGFR KRAS MUC1 MUC2
13 renal cell carcinoma, nonpapillary 29.4 CDH1 EGFR EPCAM KRT19 KRT20 KRT7
14 hepatocellular carcinoma 29.3 ADAM17 AFP ARID1A CDH1 CTNNB1 EGFR
15 squamous cell carcinoma 29.2 CDH1 EGFR EPCAM FGFR2 KRT19 KRT7
16 pancreatic cancer 28.7 CDH1 CTNNB1 EGFR EPCAM KRAS KRT19
17 colorectal cancer 28.2 CDH1 CTNNB1 EGFR EPCAM KRAS KRT19
18 sarcomatous intrahepatic cholangiocarcinoma 12.3
19 signet ring cell intrahepatic cholangiocarcinoma 12.2
20 septooptic dysplasia 11.3
21 hepatitis 10.7
22 brain ependymoma 10.7 EGFR TP53
23 breast mucoepidermoid carcinoma 10.7 MUC1 MUC5AC
24 interval angle-closure glaucoma 10.6 IDH1 IDH2
25 filamentary keratitis 10.6 MUC1 MUC4 MUC5AC
26 proliferating trichilemmal cyst 10.6 KRT19 KRT7
27 apocrine adenoma 10.6 KRAS MUC1
28 benign breast adenomyoepithelioma 10.6 EGFR KRT7
29 cap polyposis 10.6 MUC2 MUC4 MUC5AC
30 bladder carcinoma in situ 10.6 KRT19 KRT7 TP53
31 anal gland adenocarcinoma 10.6 KRT19 KRT7 MUC5AC
32 anus adenocarcinoma 10.6 KRT19 KRT7 MUC5AC
33 pulmonary blastoma 10.6 EGFR KRAS TP53
34 cerebellar astrocytoma 10.6 IDH1 TP53
35 spiradenoma 10.6 KRT7 MUC1 TP53
36 nasal cavity adenocarcinoma 10.6 KRAS KRT7 TP53
37 breast secretory carcinoma 10.6 KRT7 MUC1 MUC4
38 adult oligodendroglioma 10.6 IDH1 IDH2
39 mucinous ovarian cystadenoma 10.6 KRT7 MUC1 MUC5AC
40 enchondroma 10.6 IDH1 IDH2
41 intracranial chondrosarcoma 10.6 IDH1 IDH2 TP53
42 bronchiolo-alveolar adenocarcinoma 10.6 EGFR KRAS KRT7
43 gliomatosis cerebri 10.6 EGFR IDH1 TP53
44 pleomorphic carcinoma 10.6 EGFR KRT7 TP53
45 liver angiosarcoma 10.6 KRAS KRT19 TP53
46 glioma susceptibility 1 10.6 IDH1 IDH2 TP53
47 hepatoid adenocarcinoma 10.6 AFP EGFR MUC1
48 lipoadenoma 10.6 KRT19 KRT7 MUC1
49 intrahepatic bile duct adenoma 10.6 AFP KRT19 KRT7
50 adult hepatocellular carcinoma 10.6 CTNNB1 TP53

Graphical network of the top 20 diseases related to Intrahepatic Cholangiocarcinoma:



Diseases related to Intrahepatic Cholangiocarcinoma

Symptoms & Phenotypes for Intrahepatic Cholangiocarcinoma

UMLS symptoms related to Intrahepatic Cholangiocarcinoma:


malaise, abdominal pain

GenomeRNAi Phenotypes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.35 ADAM17 CTNNB1 EGFR KRAS MUC1
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.02 CTNNB1 EGFR EPCAM FGFR2 MUC1

MGI Mouse Phenotypes related to Intrahepatic Cholangiocarcinoma:

43 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.35 CDH1 ARID1A CTNNB1 ADAM17 FGFR2 EGFR
2 cellular MP:0005384 10.34 ADAM17 CDH1 ARID1A FGFR2 EGFR CTNNB1
3 homeostasis/metabolism MP:0005376 10.32 CDH1 AFP ARID1A CTNNB1 ADAM17 FGFR2
4 endocrine/exocrine gland MP:0005379 10.3 CDH1 AFP ARID1A CTNNB1 ADAM17 FGFR2
5 digestive/alimentary MP:0005381 10.29 CTNNB1 ADAM17 CDH1 EGFR EPCAM FGFR2
6 growth/size/body region MP:0005378 10.29 ADAM17 CDH1 ARID1A FGFR2 EGFR IDH1
7 mortality/aging MP:0010768 10.25 ADAM17 CDH1 AFP ARID1A FGFR2 EGFR
8 embryo MP:0005380 10.24 CDH1 ARID1A CTNNB1 ADAM17 FGFR2 EGFR
9 immune system MP:0005387 10.23 CDH1 ARID1A ADAM17 FGFR2 EGFR IDH1
10 neoplasm MP:0002006 10.14 AFP CTNNB1 ARID1A CDH1 EGFR FGFR2
11 no phenotypic analysis MP:0003012 10.02 CDH1 ARID1A CTNNB1 FGFR2 EGFR EPCAM
12 hearing/vestibular/ear MP:0005377 9.97 ARID1A FGFR2 EGFR CTNNB1 KRAS TP53
13 normal MP:0002873 9.97 ADAM17 CDH1 ARID1A FGFR2 EGFR CTNNB1
14 reproductive system MP:0005389 9.85 CDH1 AFP ARID1A CTNNB1 ADAM17 FGFR2
15 pigmentation MP:0001186 9.73 CTNNB1 ADAM17 FGFR2 EGFR KRAS TP53
16 skeleton MP:0005390 9.61 ADAM17 ARID1A FGFR2 EGFR CTNNB1 KRAS
17 vision/eye MP:0005391 9.23 ADAM17 ARID1A FGFR2 EGFR CTNNB1 MUC5AC

Drugs & Therapeutics for Intrahepatic Cholangiocarcinoma

Drugs for Intrahepatic Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 113)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 2, Phase 3, Phase 1 15663-27-1 2767 441203 84093
2
Gemcitabine Approved Phase 2, Phase 3, Phase 1 95058-81-4 60750
3
Capecitabine Approved, Investigational Phase 3,Phase 1 154361-50-9 60953
4
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
5
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
6
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
7
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
8 Anti-Infective Agents Phase 2, Phase 3, Phase 1
9 Antimetabolites Phase 2, Phase 3, Phase 1
10 Antimetabolites, Antineoplastic Phase 2, Phase 3, Phase 1
11 Immunosuppressive Agents Phase 2, Phase 3, Phase 1
12 Alkylating Agents Phase 2, Phase 3
13 Antiviral Agents Phase 2, Phase 3, Phase 1
14 Liver Extracts Phase 3,Phase 2,Phase 1
15 Endothelial Growth Factors Phase 3
16 Mitogens Phase 3,Phase 1,Phase 2
17 Pharmaceutical Solutions Phase 3
18
Fluorouracil Approved Phase 2 51-21-8 3385
19
chloroquine Approved, Investigational, Vet_approved Phase 1, Phase 2 54-05-7 2719
20
Metformin Approved Phase 1, Phase 2 657-24-9 4091 14219
21
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
22
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
23
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
24
Floxuridine Approved Phase 2,Phase 1 50-91-9 5790
25
nivolumab Approved Phase 2 946414-94-4
26
Ramucirumab Approved, Investigational Phase 2 947687-13-0
27
Adenosine Approved, Investigational Phase 2 58-61-7 60961
28
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
29
Dabrafenib Approved, Investigational Phase 2 44462760 44516822
30
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
31
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
32
Osimertinib Approved Phase 2 1421373-65-0 71496458
33
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286 11431660 5005498
34
Pertuzumab Approved Phase 2 380610-27-5, 145040-37-5 2540
35 Racepinephrine Approved Phase 2 329-65-7
36
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
37
Trametinib Approved Phase 2 871700-17-3 11707110
38
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
39
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
40
Calcitriol Approved, Nutraceutical Phase 2 32222-06-3 5280453 134070
41
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
42
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
43
Doxil Approved June 1999 Phase 2 31703
44 Anti-Bacterial Agents Phase 2
45 Antibiotics, Antitubercular Phase 2
46 Bone Density Conservation Agents Phase 2
47 Calcium, Dietary Phase 2
48 Micronutrients Phase 2
49 Mitomycins Phase 2
50 Nucleic Acid Synthesis Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 59)

# Name Status NCT ID Phase Drugs
1 SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma Recruiting NCT02807181 Phase 2, Phase 3 Cisplatin-gemcitabine
2 A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma Recruiting NCT03251443 Phase 3 Apatinib
3 Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma Recruiting NCT02548195 Phase 3 oxaliplatin and gemcitabine;capecitabine
4 Gemcitabine Hydrochloride and Cisplatin With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery Recruiting NCT02200042 Phase 3 Cisplatin;Gemcitabine Hydrochloride
5 Bortezomib in Intrahepatic Cholangiocellular Carcinoma Recruiting NCT03345303 Phase 3 Bortezomib
6 Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma Not yet recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
7 A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma Withdrawn NCT03081039 Phase 3 Carboplatin;Cisplatin;Gemcitabine
8 Calcitriol in Advanced Intrahepatic Cholangiocarcinoma Unknown status NCT01039181 Phase 2 Calcitriol
9 Metformin And Chloroquine in IDH1/2-mutated Solid Tumors Unknown status NCT02496741 Phase 1, Phase 2 Metformin and chloroquine combination
10 Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma Completed NCT01912053 Phase 2
11 Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Completed NCT00753675 Phase 2 ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474
12 Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma Completed NCT01954745 Phase 2 Cabozantinib
13 Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymp Completed NCT02273739 Phase 1, Phase 2 AG-221
14 ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma Recruiting NCT03230318 Phase 2 ARQ 087
15 A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma Recruiting NCT02994251 Phase 2 gemcitabine;Cisplatin;Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C
16 Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin Recruiting NCT01648023 Phase 2 Gem-Cis or Gem-Carbo
17 Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC) Recruiting NCT01862315 Phase 2 Floxuridine (FUDR);dexamethasone;Gemcitabine;Oxaliplatin
18 Treatment for Bile Duct Cancer in the Liver Recruiting NCT02167711 Phase 2 SIRT Yttrium-90
19 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
20 Ramucirumab for Advanced Pre-Treated Biliary Cancers Recruiting NCT02520141 Phase 2 Ramucirumab
21 NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma Recruiting NCT02465060 Phase 2 Adavosertib;Afatinib;Binimetinib;Capivasertib;Crizotinib;Dabrafenib;Dasatinib;Defactinib;FGFR Inhibitor AZD4547;Larotrectinib;Osimertinib;Palbociclib;PI3K-beta Inhibitor GSK2636771;Sapanisertib;Sunitinib Malate;Taselisib;Trametinib;Vismodegib
22 Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma Active, not recruiting NCT02428855 Phase 2 Dasatinib
23 Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations Active, not recruiting NCT01752920 Phase 1, Phase 2 ARQ 087
24 Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers Active, not recruiting NCT02392637 Phase 2 Abraxane (Nab-Paclitaxel);Cisplatin;Gemcitabine
25 Liver Transplantation for Early Intrahepatic Cholangiocarcinoma Not yet recruiting NCT02878473 Phase 2
26 Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma Not yet recruiting NCT03364530 Phase 2 Gemcitabine-Oxaliplatin Regimen
27 Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer Not yet recruiting NCT03044587 Phase 2 Arm NaI-IRI + 5-FU + Leucovorin (Arm A);Arm Cisplatin + Gemcitabine (Arm B)
28 Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma Suspended NCT02415036 Phase 2 Melphalan
29 Study of Low-Dose Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Intrahepatic Cholangiocarcinoma Terminated NCT02254681 Phase 2 Gemcitabine;Cisplatin
30 Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION Terminated NCT01383746 Phase 1, Phase 2
31 Response of Hepatic Tumors to Radioembolization Withdrawn NCT01775280 Phase 2
32 Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma Completed NCT01668134 Phase 1
33 ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery Completed NCT01825603 Phase 1 ADH-1;Cisplatin;Gemcitabine Hydrochloride
34 Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma Recruiting NCT02834780 Phase 1 H3B-6527
35 Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma Recruiting NCT01525069 Phase 1 Floxuridine;Dexamethasone;Gemcitabine;Oxaliplatin
36 Phase I Study of BAY 1436032 in Patients With IDH1-mutant Solid Tumors Recruiting NCT02746081 Phase 1 BAY1436032
37 Open-Label Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS and GEM; and Compared With CIS and GEM Alone in HA-high Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangioc Recruiting NCT03267940 Phase 1 PEGylated Recombinant Human Hyaluronidase;Cisplatin;Gemcitabine;Atezolizumab
38 Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma Active, not recruiting NCT01938729 Phase 1 FLOXURIDINE;DEXAMETHASONE;GEMCITABINE
39 Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases Active, not recruiting NCT00858429 Phase 1 capecitabine
40 Tremelimumab With Chemoembolization or Ablation for Liver Cancer Active, not recruiting NCT01853618 Phase 1 Tremelimumab
41 Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Not yet recruiting NCT03257761 Phase 1 Guadecitabine
42 Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery Withdrawn NCT03117855 Phase 1 Capecitabine
43 Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma Withdrawn NCT02856568 Phase 1 Cisplatin;Gemcitabine Hydrochloride;Ricolinostat
44 Conventional or Unconventional Lymph Node Dissection During Resection of Intrahepatic Cholangiocarcinoma Unknown status NCT02526771
45 Next Generation Sequencing in Intrahepatic Cholangiocarcinoma Unknown status NCT02184871
46 Prognosis of Resection and Radiotherapy in the Treatment of Intrahepatic Cholangiocarcinoma Patients Unknown status NCT01914289
47 VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway Unknown status NCT01917370
48 TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection Unknown status NCT02588755
49 Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer Unknown status NCT02238613
50 Role of Bile Duct Resection in Major Hepatectomy Due to Intrahepatic Cholangiocarcinoma Completed NCT01862276

Search NIH Clinical Center for Intrahepatic Cholangiocarcinoma

Cochrane evidence based reviews: cholangiocarcinoma

Genetic Tests for Intrahepatic Cholangiocarcinoma

Anatomical Context for Intrahepatic Cholangiocarcinoma

MalaCards organs/tissues related to Intrahepatic Cholangiocarcinoma:

38
Liver, Lymph Node, Endothelial, Colon, T Cells, Testes, Bone

Publications for Intrahepatic Cholangiocarcinoma

Articles related to Intrahepatic Cholangiocarcinoma:

(show top 50) (show all 763)
# Title Authors Year
1
Overexpression of IL-35 in intrahepatic cholangiocarcinoma isa prognostic indicator after curative resection. ( 29446854 )
2018
2
Characterization and prognostic significance of mortalin, Bcl-2 and Bax in intrahepatic cholangiocarcinoma. ( 29434920 )
2018
3
Is there a role for Ytrrium-90 in the treatment of unresectable and metastatic intrahepatic cholangiocarcinoma? ( 29395023 )
2018
4
Impact of serum CA19-9 level on prognosis and prediction of lymph node metastasis in patients with intrahepatic cholangiocarcinoma. ( 29427472 )
2018
5
Correction to: Prognostic Factors in Overall Survival of Patients with Unresectable Intrahepatic Cholangiocarcinoma Treated by Means of Yttrium-90 Radioembolization: Results in Therapy-NaA^ve Patients. ( 29380003 )
2018
6
MicroRNA-26b-5p regulates cell proliferation, invasion and metastasis in human intrahepatic cholangiocarcinoma by targeting S100A7. ( 29387225 )
2018
7
Towards Personalized Medicine for Intrahepatic Cholangiocarcinoma: Pharmacogenomic Stratification of Patients. ( 29394502 )
2018
8
Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of I^-Catenin. ( 29415992 )
2018
9
Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity. ( 29408647 )
2018
10
Extended left hepatectomy for intrahepatic cholangiocarcinoma: hepatic vein reconstruction with in-situ hypothermic perfusion and extracorporeal membrane oxygenation. ( 29386002 )
2018
11
Induction of differentiation of intrahepatic cholangiocarcinoma cells to functional hepatocytes using an organoid culture system. ( 29434290 )
2018
12
Prognostic comparison of the 7th and 8th editions of the American Joint Commission on Cancer staging system for intrahepatic cholangiocarcinoma. ( 29450978 )
2018
13
Perioperative and long-term outcome of intrahepatic cholangiocarcinoma involving the hepatic hilus after curative-intent resection: comparison with peripheral intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma. ( 29398035 )
2018
14
Hepatocholangiocarcinoma/intrahepatic cholangiocarcinoma: are they contraindication or indication for liver transplantation? A propensity score-matched analysis. ( 29450868 )
2018
15
Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling. ( 29446253 )
2018
16
Upregulation of long nona89coding RNA CCAT2 indicates a poor prognosis and promotes proliferation and metastasis in intrahepatic cholangiocarcinoma. ( 29393466 )
2018
17
Y90 radioembolization dosimetry using a simple semi-quantitative method in intrahepatic cholangiocarcinoma: Glass versus resin microspheres. ( 29448165 )
2018
18
A significant cancer burden and high mortality of intrahepatic cholangiocarcinoma in Thailand: a nationwide database study. ( 28056836 )
2017
19
Utility of KRAS mutational analysis in the preoperative diagnosis of synchronous pancreatic cancer and intrahepatic cholangiocarcinoma: A case report. ( 29390348 )
2017
20
Mutations of candidate tumor suppressor genes at chromosome 3p in intrahepatic cholangiocarcinoma. ( 29122566 )
2017
21
CD44 Expression Is a Prognostic Factor in Patients with Intrahepatic Cholangiocarcinoma After Surgical Resection. ( 28982889 )
2017
22
Intrahepatic cholangiocarcinoma patients without indications of lymph node metastasis not benefit from lymph node dissection. ( 29371948 )
2017
23
Wip1 is associated with tumorigenity and metastasis through MMP-2 in human intrahepatic cholangiocarcinoma. ( 28915621 )
2017
24
Albumin to gamma-glutamyltransferase ratio as a prognostic indicator in intrahepatic cholangiocarcinoma after curative resection. ( 28076328 )
2017
25
Defining Long-Term Survivors Following Resection of Intrahepatic Cholangiocarcinoma. ( 28840497 )
2017
26
The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma. ( 28008570 )
2017
27
C-Reactive Protein (CRP) is a Promising Diagnostic Immunohistochemical Marker for Intrahepatic Cholangiocarcinoma and is Associated With Better Prognosis. ( 28945626 )
2017
28
Mass-forming intrahepatic cholangiocarcinoma with portal vein tumor thrombus and bile duct tumor thrombus: A case report. ( 28917216 )
2017
29
Expression and prognostic value of soluble CD97 and its ligand CD55 in intrahepatic cholangiocarcinoma. ( 28345461 )
2017
30
Intrahepatic cholangiocarcinoma arising from HBV infection may be a highly selected population for liver transplantation. ( 28759704 )
2017
31
Histopathological evidence of neoplastic progression of von Meyenburg complex to intrahepatic cholangiocarcinoma. ( 28823571 )
2017
32
The risk factors and prognostic factors of intrahepatic cholangiocarcinoma. ( 28089545 )
2017
33
Modified staging classification for intrahepatic cholangiocarcinoma based on the sixth and seventh editions of the AJCC/UICC TNM staging systems. ( 28834905 )
2017
34
Implications of Intrahepatic Cholangiocarcinoma Etiology on Recurrence and Prognosis after Curative-Intent Resection: a Multi-Institutional Study. ( 28879598 )
2017
35
Osthole induces apoptosis and suppresses proliferation via the PI3K/Akt pathway in intrahepatic cholangiocarcinoma. ( 28902342 )
2017
36
Tumoral LINE-1 hypomethylation is associated with poor survival of patients with intrahepatic cholangiocarcinoma. ( 28851390 )
2017
37
Coagulopathy associated with poor prognosis in intrahepatic cholangiocarcinoma patients after curative resection. ( 28781265 )
2017
38
Corrigendum: A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. ( 28045050 )
2017
39
Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report. ( 28946921 )
2017
40
Both plasma and tumor tissue miR-146a high expression correlates with prolonged overall survival of surgical patients with intrahepatic cholangiocarcinoma. ( 29095255 )
2017
41
Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1. ( 28241849 )
2017
42
LncRNA-CCAT1 Promotes Migration, Invasion, and EMT in Intrahepatic Cholangiocarcinoma Through Suppressing miR-152. ( 28921383 )
2017
43
MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma. ( 28194813 )
2017
44
Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. ( 28858392 )
2017
45
Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014. ( 28765978 )
2017
46
Loss of Secreted Frizzled-Related Protein-1 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma. ( 28062160 )
2017
47
Perioperative and Long-Term Outcome for Intrahepatic Cholangiocarcinoma: Impact of Major Versus Minor Hepatectomy. ( 28744741 )
2017
48
Gene alterations and epigenetic changes in intrahepatic cholangiocarcinoma. ( 27893290 )
2017
49
Periostin promotes malignant potential by induction of epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. ( 29404445 )
2017
50
KCa3.1 as an Effective Target for Inhibition of Growth and Progression of Intrahepatic Cholangiocarcinoma. ( 28775776 )
2017

Variations for Intrahepatic Cholangiocarcinoma

Expression for Intrahepatic Cholangiocarcinoma

Search GEO for disease gene expression data for Intrahepatic Cholangiocarcinoma.

Pathways for Intrahepatic Cholangiocarcinoma

Pathways related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 ADAM17 CDH1 CTNNB1 EGFR FGFR2 IDH1
2
Show member pathways
13.54 ADAM17 CDH1 CTNNB1 EGFR FGFR2 IDH1
3
Show member pathways
13.44 CTNNB1 EGFR FGFR2 KRAS KRT19 KRT20
4
Show member pathways
12.98 CDH1 CTNNB1 EGFR FGFR2 KRAS TP53
5 12.77 CDH1 CTNNB1 EGFR FGFR2 KRAS TP53
6
Show member pathways
12.66 CDH1 CTNNB1 EGFR FGFR2 KRAS
7
Show member pathways
12.36 CTNNB1 EGFR FGFR2 KRAS TP53
8
Show member pathways
12.3 KRAS MUC1 MUC2 MUC4 MUC5AC
9 12.29 CDH1 EPCAM KRT19 KRT20 KRT7 MUC1
10 12.22 CTNNB1 EGFR KRAS TP53
11
Show member pathways
12.22 CDH1 CTNNB1 EGFR KRAS MUC1 TP53
12
Show member pathways
12.17 MUC1 MUC2 MUC4 MUC5AC
13
Show member pathways
12.06 MUC1 MUC2 MUC4 MUC5AC
14 11.98 CDH1 CTNNB1 EGFR KRAS TP53
15 11.94 CDH1 CTNNB1 EPCAM MUC1
16
Show member pathways
11.89 ARID1A CDH1 CTNNB1 EGFR FGFR2 KRAS
17 11.86 CTNNB1 EGFR KRAS TP53
18
Show member pathways
11.82 MUC1 MUC2 MUC4 MUC5AC
19 11.82 CDH1 CTNNB1 EGFR KRAS RASGEF1A TP53
20 11.67 CDH1 CTNNB1 EGFR
21 11.57 CDH1 EGFR KRAS TP53
22 11.43 ADAM17 EGFR FGFR2
23 11.38 EGFR FGFR2 KRAS
24 11.35 CDH1 CTNNB1 EGFR
25 11.24 CTNNB1 EGFR TP53
26 11.18 CTNNB1 EGFR KRAS
27 11.17 EGFR FGFR2 IDH1 KRAS TP53

GO Terms for Intrahepatic Cholangiocarcinoma

Cellular components related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 catenin complex GO:0016342 9.26 CDH1 CTNNB1
2 flotillin complex GO:0016600 9.16 CDH1 CTNNB1
3 lateral plasma membrane GO:0016328 9.13 CDH1 CTNNB1 EPCAM
4 Golgi lumen GO:0005796 8.92 MUC1 MUC2 MUC4 MUC5AC
5 extracellular exosome GO:0070062 10.02 CDH1 CTNNB1 EPCAM IDH1 IDH2 KRT19

Biological processes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.85 ADAM17 CTNNB1 EGFR EPCAM FGFR2 KRAS
2 epidermal growth factor receptor signaling pathway GO:0007173 9.65 ADAM17 EGFR KRAS
3 cell-cell adhesion GO:0098609 9.62 CDH1 CTNNB1 EGFR EPCAM
4 maintenance of gastrointestinal epithelium GO:0030277 9.55 MUC2 MUC4
5 entry of bacterium into host cell GO:0035635 9.54 CDH1 CTNNB1
6 morphogenesis of embryonic epithelium GO:0016331 9.52 CTNNB1 FGFR2
7 chromatin-mediated maintenance of transcription GO:0048096 9.51 ARID1A CTNNB1
8 lung-associated mesenchyme development GO:0060484 9.49 CTNNB1 FGFR2
9 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.46 ADAM17 EGFR
10 isocitrate metabolic process GO:0006102 9.43 IDH1 IDH2
11 cellular response to indole-3-methanol GO:0071681 9.4 CDH1 CTNNB1
12 mesenchymal cell proliferation involved in lung development GO:0060916 9.26 CTNNB1 FGFR2
13 O-glycan processing GO:0016266 9.26 MUC1 MUC2 MUC4 MUC5AC
14 glyoxylate cycle GO:0006097 9.16 IDH1 IDH2
15 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.02 KRAS MUC1 MUC2 MUC4 MUC5AC

Molecular functions related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.33 CTNNB1 EGFR TP53
2 isocitrate dehydrogenase activity GO:0004448 8.96 IDH1 IDH2
3 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.62 IDH1 IDH2

Sources for Intrahepatic Cholangiocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....